Clinical and pathological diagnosis of peripheral T-cell lymphoma and emerging treatment options: A case-based discussion

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 11, 2009, Pages

  Said, Jonathan ^a   Pinter Brown, Lauren ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BELINOSTAT; CARBOPLATIN; CD2 ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; INTERFERON; LENALIDOMIDE; OX40 LIGAND; PLATINUM COMPLEX; PRALATREXATE; PREDNISOLONE; ROMIDEPSIN; VINCRISTINE; ANTINEOPLASTIC AGENT;

ANEMIA; ANGIOIMMUNOBLASTIC LYMPHADENOPATHY; APRAXIA; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW BIOPSY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOPULMONARY ARREST; CLINICAL TRIAL; CONSTIPATION; COUGHING; CUTANEOUS T CELL LYMPHOMA; CYTOTOXIC T LYMPHOCYTE; DIARRHEA; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EDEMA; EOSINOPHIL COUNT; EPISTAXIS; FATIGUE; FEVER; HUMAN; ILEUS; INFECTION; LARGE CELL LYMPHOMA; LUNG ASPERGILLOSIS; LYMPHOCYTE SUBPOPULATION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NOTE; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL T CELL LYMPHOMA; PNEUMONIA; PROGRESSION FREE SURVIVAL; RASH; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; VIRUS REACTIVATION; VOMITING; WEIGHT REDUCTION; AGED; ARTICLE; CASE REPORT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; RADIATION DOSE; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, T-CELL, PERIPHERAL; MALE; MIDDLE AGED; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 73449119609     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (19)

1. Savage KJ. Peripheral T-cell lymphomas. Blood Rev. 2007;21:201-216.
2. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Arlie House, Virginia, November 1997. J Clin Oncol. 1999;17: 3835-3849.
3. Suchi T, Lennert K, Tu LY, et al. Histopathology and immunohistochemistry of peripheral T cell lymphomas: a proposal for their classification. J Clin Pathol. 1997;40: 995-1015.
4. Ascani S, Zinzani PL, Gherlinzoni F, et al. Peripheral T-cell lymphomas. Clinicopathologic study of 168 cases diagnosed according to the R.E.A.L. classification. Ann Oncol. 1997;8:583-592.
5. Gisselbrecht C, Gaulard P, Lepage E, et al. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Blood. 1998;92:76-82.
6. Lopez-Guillermo A, Cid J, Salar A, et al. Peripheral T-cell lymphomas: initial features, natural history and prognostic factors in a series of 174 patients diagnosed according to the REAL classification. Ann Oncol. 1998;9:849-855.
7. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood. 1994;84:1361-1392.
8. Feller AC, Griesser GH, Mak TW, Lennert K. Lymphoepithelioid lymphoma (Lennert's lymphoma) is a monoclonal proliferation of helper/inducer T cells. Blood. 1986;68:663-667.
9. Jiang L, Jones D, Medeiros LJ, et al. Peripheral T-cell lymphoma with a "follicular" pattern and the perifollicular sinus phenotype. Am J Clin Pathol. 2005;123:448-455.
10. Went P, Agostinelli C, Gallamini A, et al. Marker expression in peripheral T-cell lymphoma: a proposed clinical-pathologic prognostic score. J Clin Oncol. 2006;24:2472-2479.
11. Piris M, Brown DC, Gatter KC, Mason DY. CD30 expression in non-Hodgkin's lymphoma. Histopathology. 1990;17:211-218.
12. Barry TS, Jaffe ES, Sorbara L, et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol. 2003;27:1513-1522.
13. Gorczyca W, Tsang P, Liu Z, et al. CD30-positive T-cell lymphomas co-expressing CD15: an immunohistochemical analysis. Int J Oncol. 2003;22:319-324.
14. Grogg KL, Attygalle AD, Macon WR, et al. Expression of CXCL13, a chemokine highly upregulated in germinal center T-helper cells, distinguishes angioimmunoblastic T-cell lymphoma from peripheral T-cell lymphoma, unspecified. Mod Pathol. 2006;19:1101-1107.
15. Grogg KL, Attygalle AD, Macon WR, et al. Angioimmunoblastic T-cell lymphoma: a neoplasm of germinal-center T-helper cells? Blood. 2005;106:1501-1502.
16. Asano N, Suzuki R, Kagami Y, et al. Clinicopathologic and prognostic significance of cytotoxic molecule expression in nodal peripheral T-cell lymphoma, unspecified. Am J Surg Pathol. 2005;29:1284-1293.
17. Dupuis J, Emile JF, Mounier N, et al. Prognostic significance of Epstein-Barr virus in nodal peripheral T-cell lymphoma, unspecified: a Groupe d'Etude des Lymphomes de l'Adulte (GELA) study. Blood. 2006;108:4163-4169.
18. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology: Non-Hodgkin's Lymphoma, V3.2009. Available at http://www.nccn.org/ professionals/physician-gls/PDF/nhl.pdf.
19. Gallamini A, Stelitano C, Calvi R, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study. Blood. 2004;103:2474-2479.